EU/3/18/2047: Orphan designation for the treatment of phosphomannomutase 2-congenital disorder of glycosylation

liposomal mannose-1-phosphate

Overview

On 31 July 2018, orphan designation (EU/3/18/2047) was granted by the European Commission to Glycomine SARL, France, for liposomal mannose-1-phosphate for the treatment of phosphomannomutase 2-congenital disorder of glycosylation.

The sponsorship was transferred to Regintel Limited, Ireland, in May 2020.

Key facts

Active substance
liposomal mannose-1-phosphate
Intended use
treatment of phosphomannomutase 2-congenital disorder of glycosylation
Orphan designation status
Positive
EU designation number
EU/3/18/2047
Date of designation
31/07/2018
Sponsor

RegIntel Limited
Templetown
Carlingford
A91 T923
County Louth
Ireland
E-mail: bmartin@regintel.com 

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
1 rating